ChineseInvestors.com, Inc. (CIIX) Debuts “OptHem
Post# of 346
(Total Views: 224)
Posted On: 05/30/2017 6:11:06 PM
ChineseInvestors.com, Inc. (CIIX) Debuts “OptHemp” Premium Line and Readies its First U.S. Retail Store
ChineseInvestors.com’s (OTCQB: CIIX) first retail store is expected to open in June in San Gabriel, California. It will be among the first stores to sell “OptHemp,” a premium health product line launched by CIIX’s wholly owned subsidiary chinesehempoil.com, Inc. The “OptHemp” line will include OptHemp Ultra Premium Hemp Oil, the company’s first private label product.
CIIX offers educational tools and consulting services for Chinese investors. Recently, it has been pursuing its niche in the expanding cannabis (CBD) market. The company’s goal is to become a leading Chinese publicly traded company in the nutritional industry. CIIX’s retail store in California will primarily sell hemp oil-based products, which it will market via a new website, mobile application, and online distribution program to penetrate the rapidly growing hemp-based CBD market.
“I am very pleased to announce the launch of our first premium OptHemp product,” Warren Wang, founder and CEO of CIIX, stated in a recent news release. “Hemp oil is believed to have positive balancing effects on the mind and body of persons using them.”
The formula for OptHemp has been optimized to manage inflammation and pain relief. The OptHemp premium line is GMO-free, reinforcing the product’s purity to users. It is grown in organic farms in Colorado using a CO2 extraction technology.
“We believe that the desire for better quality of life in the Chinese community, coupled with the fact that the aging population continues to grow, will lead to continued growth in the alternative health sector and increased demand for natural hemp-based health products,” Wang said. “CIIX is confident that its OptHemp product line will lay a solid foundation for the Company’s entrance into the legal hemp industry and the alternative health sector.”
In the future, CIIX will focus on the distribution and R&D into the CBD market. Its products can be used for patients with epilepsy, Alzheimer’s disease, and cirrhosis of the liver. In China, use of marijuana is forbidden, though hemp-based CBDs are legal, creating a target market of approximately 2 billion consumers.
For more information, visit the company’s website at www.ChineseInvestors.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
ChineseInvestors.com’s (OTCQB: CIIX) first retail store is expected to open in June in San Gabriel, California. It will be among the first stores to sell “OptHemp,” a premium health product line launched by CIIX’s wholly owned subsidiary chinesehempoil.com, Inc. The “OptHemp” line will include OptHemp Ultra Premium Hemp Oil, the company’s first private label product.
CIIX offers educational tools and consulting services for Chinese investors. Recently, it has been pursuing its niche in the expanding cannabis (CBD) market. The company’s goal is to become a leading Chinese publicly traded company in the nutritional industry. CIIX’s retail store in California will primarily sell hemp oil-based products, which it will market via a new website, mobile application, and online distribution program to penetrate the rapidly growing hemp-based CBD market.
“I am very pleased to announce the launch of our first premium OptHemp product,” Warren Wang, founder and CEO of CIIX, stated in a recent news release. “Hemp oil is believed to have positive balancing effects on the mind and body of persons using them.”
The formula for OptHemp has been optimized to manage inflammation and pain relief. The OptHemp premium line is GMO-free, reinforcing the product’s purity to users. It is grown in organic farms in Colorado using a CO2 extraction technology.
“We believe that the desire for better quality of life in the Chinese community, coupled with the fact that the aging population continues to grow, will lead to continued growth in the alternative health sector and increased demand for natural hemp-based health products,” Wang said. “CIIX is confident that its OptHemp product line will lay a solid foundation for the Company’s entrance into the legal hemp industry and the alternative health sector.”
In the future, CIIX will focus on the distribution and R&D into the CBD market. Its products can be used for patients with epilepsy, Alzheimer’s disease, and cirrhosis of the liver. In China, use of marijuana is forbidden, though hemp-based CBDs are legal, creating a target market of approximately 2 billion consumers.
For more information, visit the company’s website at www.ChineseInvestors.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)